VenicMAb™ Caninized Anti-Canine VEGF Monoclonal Antibody- R41

Canine Vascular Endothelial Growth Factor (VEGF) is a crucial protein involved in angiogenesis, the process by which new blood vessels form from pre-existing ones. This protein plays a significant role in both normal physiological processes and pathological conditions, such as cancer, where it promotes tumor growth by enhancing blood supply. Anti-canine VEGF monoclonal antibodies could be targeted therapies specifically bind to VEGF, inhibiting its activity and thereby preventing tumor vascularization. This could be a potential approach that holds promise for improving cancer treatment outcomes in dogs, offering a more effective and targeted strategy to manage malignancies.